Navigation Links
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Date:8/11/2009

t candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

    CONTACT: Amgen, Thousand Oaks
    Sarah Reines: (805) 447-9783 (media, osteoporosis)
    Lisa Rooney: (805) 447-6437 (media, oncology)
    Arvind Sood: (805) 447-1060 (investors)

(Logo:

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... your doctor know what you,re smoking?  Chances are, probably not.  ... over 112,000 currently registered patients under Colorado,s ... 20,300+ active physicians listed with the Colorado Dept of Regulatory ... a poll in February 2014 showed 51% of ... "With marijuana legalization underway, every doctor needs a ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... in Patients Following Bunionectomy, TAMPA, Fla., May ... several days following removal of a,bunion, one of ... tapentadol provided significant relief for patients who had ... with tapentadol,also resulted in patients reporting fewer gastrointestinal ...
... X-ray ... Data -, ... two-year Phase III study showing that ACTEMRA(TM),(tocilizumab) can significantly inhibit progression of ... of,effectiveness of an RA treatment. The study also demonstrated that ACTEMRA,reduces disease ...
Cached Medicine Technology:New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... 2014 Hastings and Hastings, a qualified ... throughout Arizona is pleased to report having saved a ... example among many cases where Hastings and Hastings has ... retain a greater portion of their settlement or recovery. ... a positive solution for Arizona car accident victims is ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... development company in India, Profit By Outsourcing is ... Web Development services. The company gives emphasize on putting ... the complete product to clients. Their dedicated team of ... attaining ground-breaking results. They can handle even the critical ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Removecomplaints.net, a ... management industry, has announced to offer guarantee of results ... to offer this guarantee because of its tremendous track ... 200 clients from all over the world and received ... good job. , On being asked about the ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2
... associated with loss of blood supply to the brain , , ... type of depression in the elderly related to blood vessels ... have discovered why some patients with this condition fail to ... to be presented Wednesday during a news conference by researchers ...
... million, up 20% from first quarter ... - EPS of $0.38, up 36% from first quarter 2007, - Record new ... 2007, ... ...
... been made in reducing the harm of tobacco in ... ... Tomorrow marks the 10-year,anniversary of Minnesota,s historic settlement with the ... national headlines for,exposing millions of tobacco industry documents and for creating ...
... MELVILLE, N.Y., May 6 Today, Fougera, ... has received FDA approval to bring to ... (Rx) (Scalp,Solution). The generic formulation compares to ... ), Fougera,s Calcipotriene Topical Solution is ...
... Calif., May 6 Capitol Chiropractic,Buckle-Up Safe Day 2008 will ... noon and 3:30 p.m. to 6:30 p.m. at 9500 Micron ... great way to help prevent and/or reduce,car crash injuries to ... way of giving back to our community, through teaching simple ...
... Open Course in Celebrity Foursome, WASHINGTON, May 6 ... cancer survivor, John,Atkinson has won the Golf Digest U.S. ... over 56,000 entries., He will try to break ... the,pros for this year,s U.S. Open. Atkinson will compete ...
Cached Medicine News:Health News:Several Therapies Show Promise for Vascular Depression 2Health News:Several Therapies Show Promise for Vascular Depression 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 4Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 5Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 6Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 7Health News:ClearWay Minnesota(SM) Celebrates 10-Year Anniversary of Settlement 2Health News:Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution) 2Health News:Sacramento Chiropractor Takes Aim at Reducing Car Accident Injuries 2Health News:Lung Cancer Alliance Advocate Wins Golf Digest Contest 2
... The Stockert 70 RF ... the EP lab every day, ... the Stockert 70 and the ... NAVI-STAR Diagnostic/Temperature Ablation Catheter provide ...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... The Identity pacemaker family, ... dual-chamber pacemaker, provides clinicians with ... available, including the revolutionary AF ... only U.S. commercially approved algorithm ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: